GLP-1 drugs for weight loss, like Saxenda and Wegovy , are FDA-approved for people with obesity (defined as a body mass index , or BMI, of 30 or higher ) or with a BMI of 27 or higher and a weight-related health condition, such as high cholesterol, type 2 diabetes, or high blood pressure
Yes, because BPC-157 is an experimental compound intended for therapeutic use, it should only be used under the supervision of a licensed healthcare provider
Ensuring adequate protein intake and a balanced diet supports overall nerve health
Marketing and Distribution Costs Pharmaceutical companies spend substantial amounts on marketing to healthcare providers and consumers, patient support programs, training materials for providers, and extensive distribution networks
Patients are embracing these options to: Break through stubborn plateaus after diet and exercise Reduce food noise, or constant preoccupation with eating Improve metabolic markers like blood sugar and cholesterol Lower the risks associated with being overweight or obese GLP-1 medications are now part of a broader movement toward medical weight loss management in medspas, giving clients science-based momentum for their health goals